Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4)

INTRODUCTION: Pulmonary arterial hypertension (PAH) is associated with poor prognosis despite significant recent advances in its treatment. An intravenous formulation of epoprostenol sodium containing glycine and mannitol (epoprostenol GM; GlaxoSmithKline, London, UK) is widely used to treat PAH. A...

Descripción completa

Detalles Bibliográficos
Autores principales: Tamura, Yuichi, Ono, Tomohiko, Fukuda, Keiichi, Satoh, Toru, Sasayama, Shigetake
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2013
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680653/
https://www.ncbi.nlm.nih.gov/pubmed/23653230
http://dx.doi.org/10.1007/s12325-013-0029-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3680653/
https://www.ncbi.nlm.nih.gov/pubmed/23653230
http://dx.doi.org/10.1007/s12325-013-0029-0

Ejemplares similares